William Blair Weighs in on Sarepta Therapeutics, Inc.’s Q4 2018 Earnings (SRPT)
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Analysts at William Blair issued their Q4 2018 earnings per share (EPS) estimates for Sarepta Therapeutics in a research note issued on Friday. William Blair analyst T. Lugo forecasts that the biotechnology company will earn ($0.39) per share for the quarter. William Blair currently has a “Outperform” rating on the stock.
Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.92) by $0.46. The business had revenue of $35.01 million during the quarter, compared to analyst estimates of $22.52 million. During the same period last year, the firm posted ($1.19) earnings per share. The company’s quarterly revenue was up 350000.0% on a year-over-year basis.
A number of other analysts have also recently weighed in on SRPT. Credit Suisse Group reissued an “outperform” rating and issued a $81.00 target price on shares of Sarepta Therapeutics in a research note on Monday. Morgan Stanley restated an “equal weight” rating and set a $31.00 price target on shares of Sarepta Therapeutics in a research note on Friday, June 30th. Leerink Swann restated an “outperform” rating on shares of Sarepta Therapeutics in a research note on Monday, July 3rd. Robert W. Baird reaffirmed an “outperform” rating and set a $96.00 price objective (down from $102.00) on shares of Sarepta Therapeutics in a report on Friday, July 21st. Finally, Zacks Investment Research raised Sarepta Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, August 2nd. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and fifteen have assigned a buy rating to the stock. Sarepta Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $62.79.
Shares of Sarepta Therapeutics (NASDAQ SRPT) traded up 1.44% during midday trading on Monday, hitting $49.89. 1,086,084 shares of the company were exchanged. The stock’s market cap is $3.21 billion. Sarepta Therapeutics has a one year low of $26.26 and a one year high of $63.03. The stock’s 50-day moving average is $42.47 and its 200-day moving average is $35.98.
In other news, SVP Shamim Ruff sold 12,138 shares of the business’s stock in a transaction on Friday, July 21st. The stock was sold at an average price of $42.97, for a total transaction of $521,569.86. Following the completion of the sale, the senior vice president now owns 27,312 shares in the company, valued at $1,173,596.64. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Douglas S. Ingram purchased 47,058 shares of the business’s stock in a transaction dated Thursday, July 27th. The shares were purchased at an average cost of $42.50 per share, for a total transaction of $1,999,965.00. Following the purchase, the chief executive officer now directly owns 382,058 shares of the company’s stock, valued at $16,237,465. The disclosure for this purchase can be found here. Insiders sold a total of 78,056 shares of company stock worth $3,224,208 over the last quarter. Corporate insiders own 9.60% of the company’s stock.
A number of institutional investors have recently bought and sold shares of SRPT. BlackRock Inc. boosted its holdings in Sarepta Therapeutics by 4,403.1% in the first quarter. BlackRock Inc. now owns 5,292,729 shares of the biotechnology company’s stock valued at $156,664,000 after acquiring an additional 5,175,193 shares during the last quarter. Camber Capital Management LLC acquired a new stake in Sarepta Therapeutics in the first quarter worth about $39,960,000. State Street Corp raised its holdings in Sarepta Therapeutics by 21.2% during the 1st quarter. State Street Corp now owns 3,197,127 shares of the biotechnology company’s stock worth $94,641,000 after purchasing an additional 559,342 shares during the last quarter. Voya Investment Management LLC raised its holdings in Sarepta Therapeutics by 2,786.1% during the 2nd quarter. Voya Investment Management LLC now owns 568,525 shares of the biotechnology company’s stock worth $19,165,000 after purchasing an additional 548,826 shares during the last quarter. Finally, HealthCor Management L.P. raised its holdings in Sarepta Therapeutics by 31.1% during the 2nd quarter. HealthCor Management L.P. now owns 2,031,890 shares of the biotechnology company’s stock worth $68,495,000 after purchasing an additional 481,890 shares during the last quarter. Institutional investors and hedge funds own 65.41% of the company’s stock.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.